ASCO News: Cemiplimab (Libtayo, Regeneron Pharmaceuticals, Inc.) Performs Well in High-risk cSCC in the Adjuvant Setting
Cemiplimab (Libtayo, Regeneron Pharmaceuticals, Inc.) produced a statistically significant and clinically meaningful benefit in high-risk cutaneous squamous cell carcinoma (CSCC) after surgery, according to the Phase 3 C-POST trial.